Penumbra, Inc. (PEN) is a Healthcare stock trading at $323.95 (as of 2026-08-20), with a market capitalization of $12.76B and a trailing P/E of 87.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Penumbra makes neurovascular medical devices, including aspiration based thrombectomy systems and embolization coiling systems, and it earns revenue from selling these products and related accessory devices.
The profit model is driven primarily by selling thrombectomy systems and their related revascularization devices and accessories (with additional contribution from neurovascular embolization and access product sales).
| ThrombectomyProd | $0.3B |
| EmbolAccess | $0.1B |
Business quality (Mixed): Gross margins are high (67.6%), while operating margin is lower (10.2%), suggesting meaningful costs below gross profit and a profit profile that depends on product sales and operating expense discipline.
Valuation: At 73× earnings, PEN trades 126% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $323.95 |
| Market Cap | $12.76B |
| P/E Ratio | 87.5 |
| EV / EBITDA | 63.2 |
| Price / Book | 8.34 |
| Price / Sales | 8.54 |
| FCF Yield | 2.8% |
| DCF Value (model) | $81.08 |
| DCF Upside vs Price | -75.0% |
| Revenue (TTM) | $1.40B |
| Net Margin | 12.7% |
| Revenue Growth (YoY) | 17.5% |
| EPS Growth (YoY) | 1169.4% |
| FCF Growth (YoY) | 18.8% |
| Altman Z-Score | 21.09 (safe) |
| Stock P/E | 87.5 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | 305.1% |
| vs Industry | 166.1% |
| Top Institutional Holder | Decagon Asset Management LLP ($55.03B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 1 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Adam Elsesser |
| Employees | 4,500 |
| Country | US |
| IPO Date | 2015-09-18 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.